Kerendia 10 mg is a tablet formulation of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist [1]. It is used to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, kidney death, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1][2].
How does Kerendia work?
Kerendia works by blocking the harmful effects of excessive mineralocorticoid receptor (MR) activity [1]. In conditions like chronic kidney disease and type 2 diabetes, overactivation of the MR system can lead to inflammation, fibrosis, and cellular damage in the kidneys and heart [1][3]. By selectively inhibiting the MR, Kerendia helps to mitigate these damaging processes [1].
What are the available strengths of Kerendia?
Kerendia is available in two oral tablet strengths: 10 mg and 20 mg [1]. The starting dose is typically 10 mg once daily [1].
When does Kerendia's patent expire?
The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, such as its composition, method of use, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiry dates, which can be relevant for understanding when generic versions might become available [4]. Information on specific patent expiry dates for Kerendia can be found on specialized patent tracking websites.
What clinical data supports Kerendia's use?
Kerendia's efficacy and safety have been demonstrated in clinical trials, notably the FIDELIO-DKD and FIGARO-DKD studies [1][2]. These studies showed that Kerendia, when added to standard care, significantly reduced the risk of kidney and cardiovascular outcomes in patients with CKD and type 2 diabetes [1][2].
What are the risks and side effects associated with Kerendia?
Common side effects of Kerendia include hyperkalemia (high potassium levels in the blood), hypotension (low blood pressure), and fatigue [1]. Patients taking Kerendia require regular monitoring of potassium levels and kidney function [1][3].
How does Kerendia compare to other treatments for CKD in type 2 diabetes?
Kerendia offers a novel mechanism of action by selectively targeting the mineralocorticoid receptor, distinct from other CKD treatments that focus on blood pressure control (e.g., ACE inhibitors, ARBs) or glucose management [3]. Its clinical trial data specifically supports its benefit in reducing both kidney and cardiovascular events in this patient population [1][2].
---
Sources
1. DrugPatentWatch.com
2. FDA Approved Drugs
3. Kerendia (finerenone) Prescribing Information
4. National Institutes of Health (NIH)